In the phase 2 BASALT‐1 trial, buparlisib was given to previously treated NSCLC patients with PI3K pathway alterations, but this and further buparlisib combination trials with chemotherapy or gefitinib, the latter in EGFR resistance, failed to show any efficacy [267–269]. Here, EGFR is linked to non-small cell lung carcinoma.